Synthesis and aldose reductase inhibitory activity of 5-arylidene-2,4-thiazolidinediones

被引:252
作者
Bruno, G
Costantino, L
Curinga, C
Maccari, R
Monforte, F
Nicolò, F
Ottanà, R
Vigorita, MG
机构
[1] Univ Messina, Fac Farm, Dipartimento Farmacochim, I-98168 Messina, Italy
[2] Univ Modena & Reggio Emilia, Fac Farm, Dipartimento Sc Farmaceut, I-41100 Modena, Italy
[3] Univ Messina, Fac Sci MMFFNN, Dipartimento Ch Inorg Chim Anal & Ch Fis, I-98166 Messina, Italy
关键词
D O I
10.1016/S0968-0896(01)00366-2
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
Several (Z)-5-arylidene-2,4-thiazolidinediones were synthesized and tested as aldose reductase inhibitors (ARIs). The most active of the N-unsubstituted derivatives (2) exerted the same inhibitory activity of Sorbinil. The introduction of an acetic side chain on N-3 of the thiazolidinedione moiety led to a marked increase in lending inhibitory activity, conducting to the discovery of a very potent ARI (4c), whose activity level (IC50=0.13 muM) was in the same range of Tolrestat. Moreover, the corresponding methyl esters (3), devoid of any acidic functionality, showed appreciable inhibitory activity similar to that of the N-unsubstituted compounds. It was also found that the substitution pattern on the 5-benzylidene moiety markedly influenced the activity of N-unsubstituted 2,4-thiazolidinediones 2, compounds with substituents at the meta position being generally more effective than the para-substituted ones, however, this SAR was not evidenced in acetates 3 and acids 4. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1077 / 1084
页数:8
相关论文
共 40 条
[1]
[[OMEGA-(HETEROCYCLYLAMINO)ALKOXY]BENZYL]-2,4-THIAZOLIDINEDIONES AS POTENT ANTIHYPERGLYCEMIC AGENTS [J].
CANTELLO, BCC ;
CAWTHORNE, MA ;
COTTAM, GP ;
DUFF, PT ;
HAIGH, D ;
KINDLEY, RM ;
LISTER, CA ;
SMITH, SA ;
THURLBY, PL .
JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (23) :3977-3985
[2]
CASTANER J, 1991, Drugs of the Future, V16, P895
[3]
Castaner J., 1987, DRUGS FUTURE, V12, P336
[4]
Pharmacological approaches to the treatment of diabetic complications [J].
Costantino, L ;
Rastelli, G ;
Gamberini, MC ;
Barlocco, D .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2000, 10 (08) :1245-1262
[5]
Costantino L, 1999, MED RES REV, V19, P3, DOI 10.1002/(SICI)1098-1128(199901)19:1<3::AID-MED2>3.0.CO
[6]
2-7
[7]
New aldose reductase inhibitors as potential agents for the prevention of long-term diabetic complications [J].
Costantino, L ;
Rastelli, G ;
Cignarella, G ;
Vianello, P ;
Barlocco, D .
EXPERT OPINION ON THERAPEUTIC PATENTS, 1997, 7 (08) :843-858
[8]
Synthesis, activity, and molecular modeling of a new series of tricyclic pyridazinones as selective aldose reductase inhibitors [J].
Costantino, L ;
Rastelli, G ;
Vescovini, K ;
Cignarella, G ;
Vianello, P ;
DelCorso, A ;
Cappiello, M ;
Mura, U ;
Barlocco, D .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (22) :4396-4405
[9]
El-Kabbani O, 1999, MOL VIS, V5, pU1
[10]
Synthesis, activity, and molecular modeling of new 2,4-dioxo-5-(naphthylmethylene)-3-thiazolidineacetic acids and 2-thioxo analogues as potent aldose reductase inhibitors [J].
Fresneau, P ;
Cussac, M ;
Morand, JM ;
Szymonski, B ;
Tranqui, D ;
Leclerc, G .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (24) :4706-4715